GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier

[1]  W. Koltun,et al.  Increase in the Tight Junction Protein Claudin-1 in Intestinal Inflammation , 2011, Digestive Diseases and Sciences.

[2]  C. Weber,et al.  Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function , 2011, The Journal of cell biology.

[3]  C. Wood,et al.  Cortisol reduces paracellular permeability and increases occludin abundance in cultured trout gill epithelia , 2010, Molecular and Cellular Endocrinology.

[4]  A. Buchman,et al.  Teduglutide, a novel mucosally active analog of glucagon‐like peptide‐2 (GLP‐2) for the treatment of moderate to severe Crohn's disease , 2010, Inflammatory bowel diseases.

[5]  Qiurong Li,et al.  Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  T. Nishida,et al.  Up‐regulation of the tight‐junction protein ZO‐1 by substance P and IGF‐1 in A431 cells , 2009, Cell biochemistry and function.

[7]  T. Nishida,et al.  Up‐regulation of ZO‐1 expression and barrier function in cultured human corneal epithelial cells by substance P , 2009, FEBS letters.

[8]  W. Loomis,et al.  Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated Caco-2 intestinal monolayers. , 2009, Life sciences.

[9]  A. Yu,et al.  Biology of claudins. , 2008, American journal of physiology. Renal physiology.

[10]  E. Mazzon,et al.  Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[11]  L. Wallace,et al.  Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[12]  W. Koltun,et al.  Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. , 2007, The Journal of surgical research.

[13]  U Wahnschaffe,et al.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease , 2006, Gut.

[14]  J. Holst,et al.  Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. , 2006, The American journal of clinical nutrition.

[15]  T. Matsui,et al.  ZO-1 and ZO-2 Independently Determine Where Claudins Are Polymerized in Tight-Junction Strand Formation , 2006, Cell.

[16]  P. Beck,et al.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. , 2006, World journal of gastroenterology.

[17]  S. Tsukita,et al.  Claudins in occluding junctions of humans and flies. , 2006, Trends in cell biology.

[18]  D. Ye,et al.  Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[19]  C. V. Van Itallie,et al.  Claudins and epithelial paracellular transport. , 2006, Annual review of physiology.

[20]  P. Jeppesen.  Glucagon-like peptide-2: update of the recent clinical trials. , 2006, Gastroenterology.

[21]  M. Zeitz,et al.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.

[22]  K. Kaukinen,et al.  Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells , 2005, Laboratory Investigation.

[23]  J. Mclaughlin,et al.  Ochratoxin A increases permeability through tight junctions by removal of specific claudin isoforms. , 2004, American journal of physiology. Cell physiology.

[24]  F. Schmitz,et al.  Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro—evidence for a TGF-β-mediated effect , 2004, Regulatory Peptides.

[25]  K. Kuenzler,et al.  Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. , 2004, Journal of pediatric surgery.

[26]  A. Pedram,et al.  TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation , 2004 .

[27]  S. Ashley,et al.  Glucagon-Like Peptide 2 Stimulates Intestinal Epithelial Proliferation In Vitro , 2002, Digestive Diseases and Sciences.

[28]  A. Pedram,et al.  TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[29]  F. Schmitz,et al.  Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect. , 2004, Regulatory peptides.

[30]  Sven Frokjaer,et al.  In-depth evaluation of Gly-Sar transport parameters as a function of culture time in the Caco-2 cell model. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  P. Brubaker,et al.  Glucagon-Like Peptide-2 and Common Therapeutics in a Murine Model of Ulcerative Colitis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[32]  J. Schulzke,et al.  Epithelial Barrier Defects in HT‐29/B6 Colonic Cell Monolayers Induced by Tumor Necrosis Factor‐α , 2000, Annals of the New York Academy of Sciences.

[33]  P. Yang,et al.  Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse , 2000, Gut.

[34]  D. Drucker,et al.  New frontiers in the biology of GLP-2 , 2000, Regulatory Peptides.

[35]  J. Palazzo,et al.  Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. , 2000, Journal of pediatric surgery.

[36]  B. Yusta,et al.  Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. , 1999, The American journal of physiology.

[37]  J. Schulzke,et al.  Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. , 1999, Gastroenterology.

[38]  B. Yusta,et al.  Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. , 1999, The American journal of physiology.

[39]  D. McKay,et al.  Superantigen activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via IFN-gamma and TNF alpha: inhibition of increased permeability, but not diminished secretory responses by TGF-beta2. , 1997, Journal of immunology.

[40]  G. May,et al.  Is small intestinal permeability really increased in relatives of patients with Crohn's disease? , 1993, Gastroenterology.

[41]  J. M. Mullin,et al.  Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. , 1990, Cancer research.

[42]  J. Rotter,et al.  Intestinal permeability in patients with Crohn's disease and their healthy relatives. , 1989, Gastroenterology.

[43]  J. Rotter,et al.  Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. , 1986, Annals of internal medicine.

[44]  S. Ukabam,et al.  Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. , 1983, Digestion.